Bristol Myers Squibb sues Biden administration over Medicare drug negotiations in third such lawsuit

Bristol Myers Squibb on Friday sued the Biden administration over Medicare’s new powers to negotiate drug prices, the third such lawsuit to be filed against the program in a matter of days.

The lawsuit, filed in federal district court in New Jersey, argues the Medicare negotiations violate the First and Fifth Amendments of the U.S. Constitution.

Bristol Myers Squibb has asked the court to declare the program unconstitutional and prevent the Health and Human Services Department from forcing the company to enter negotiations.

The drugmaker’s arguments mirror those lodged by drugmaker Merck last week, which was the first company to sue the federal government over the drug negotiations.

The U.S. Chamber of Commerce has also sued HHS over the program with similar arguments.

Bristol Myers Squibb said its blood thinner Eliquis, used to treat clots and strokes, will be subject to the negotiations this year. The company generated $11.8 billion in revenue from Eliquis last year, about 25% of the company’s $46 billion in total revenue for 2022.

The drugmaker said Opdivo, used to treat several types of cancer, will be subject to the Medicare negotiations in the future. Opdivo generated $8.2 billion in sales for the company in 2022, which made up about 18% of the drugmaker’s total revenue for that year.

Bristol Myers Squibb argued that the federal government is forcing the company to enter negotiations and eventually agree to a heavily discounted price. The company claims this violates 5th Amendment protections against the government seizing private property for public use without just compensation.

This is breaking news. Please check back for updates.